Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
January 03, 2018 08:30 ET
|
Spark Therapeutics, Inc.
Company offers outcomes-based rebates and an innovative contracting model that support patient access in the U.S. while aiming to reduce risk and financial burden for payers and treatment centers ...
Spark Therapeutics to Participate in Multiple Conferences in January
January 02, 2018 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
December 19, 2017 15:05 ET
|
Spark Therapeutics, Inc.
LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved...
Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2017 07:45 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2017 07:00 ET
|
Spark Therapeutics, Inc.
Data include eleventh participant in the trial Annualized bleeding rate (ABR) for all 11 participants was reduced by 97 percent, while annualized infusion rate (AIR) was reduced 99 percent as of...
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
December 06, 2017 17:00 ET
|
Spark Therapeutics, Inc.; Pfizer Inc.
PHILADELPHIA and NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
December 05, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
November 10, 2017 17:05 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
November 07, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease,...
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
November 07, 2017 07:15 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA and NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) today announced they have entered into an amendment to their license...